12/10
12:21 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
12/10
12:21 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
12/9
06:22 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
12/9
07:30 am
vor
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
High
Report
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
11/12
08:00 am
vor
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Medium
Report
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
11/8
10:05 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
11/8
08:46 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
High
Report
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
11/7
04:05 pm
vor
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
High
Report
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
10/1
07:13 am
vor
C-suite leaders race to keep up with the rapid pace of AI before competitors take the lead [Fortune]
High
Report
C-suite leaders race to keep up with the rapid pace of AI before competitors take the lead [Fortune]
9/30
07:00 am
vor
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Low
Report
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer